Biomedical Engineering Reference
In-Depth Information
Schwartz, L. H., Shankar, L., and Therasse, P. (2009).
Recommendations for
the assessment of progression in randomised cancer treatment trials.
European
Journal of Cancer 45, 281{289.
Dodd, L. E., Korn, E. L., Freidlin, B., Jaffe, C. C., Rubinstein, L. V., Dancey, J.,
and Mooney, M. M. (2008). Blinded independent central review of progression-
free survival in phase III clinical trials: Important design element or unnecessary
expense? Journal of Clinical Oncology 26, 3791{3796.
Efron, B. (1977).
The eciency of Cox's likelihood function for censored data.
Journal of the American Statistical Association 72, 557{565.
FDA (2004).
Center for Drug Evaluation and Research: Oncologic Drugs Advi-
sory Committee, May 3-4, Genasense briefing material. Accessed October 2011,
available at
http://www.fda.gov/ohrms/dockets/ac/04/briefing/4037b1.htm
.
FDA
(2006).
Center
for
Drug
Evaluation
and
Research:
Oncologic
Drugs
Advisory
Committee,
March
13,
Gemzar
brieng
material.
Accessed
on October 2011, available at
http://www.fda.gov/ohrms/dockets/
ac/06/briefing/2006-4203b1-index.htm
.
FDA
(2007).
Guidance
for
industry:
Clinical
trial
endpoints
for
the approval of cancer drugs and biologics. Accessed Octo-
ber 2011, available at
http://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf
.
Finkelstein, D. M. (1986). A proportional hazards model for interval-censored failure
time data. Biometrics 42, 845{854.
Freidlin, B., Korn, E. L., Hunsberger, S., Gray, R., Saxman, S., and Zujewski, J. A.
(2007). Proposal for the use of progression-free survival in unblinded randomized
trials. Journal of Clinical Oncology 25, 2122{2126.
Gray, R., Bhattacharya, S., Bowden, C., Miller, K., and Comis, R. L. (2009). Inde-
pendent review of e2100: A phase III trial of bevacizumab plus paclitaxel versus
paclitaxel in women with metastatic breast cancer. Journal of Clinical Oncology
27, 4966{4972.
Search WWH ::
Custom Search